DelveInsight’s, “Leiomyosarcoma Pipeline Insight, 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Leiomyosarcoma pipeline landscape. It covers the Leiomyosarcoma pipeline drug profiles, including Leiomyosarcoma clinical trials and nonclinical stage products. It also covers the Leiomyosarcoma pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Leiomyosarcoma emerging drugs, the Leiomyosarcoma pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Leiomyosarcoma pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Leiomyosarcoma Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Leiomyosarcoma clinical trials studies, Leiomyosarcoma NDA approvals (if any), and product development activities comprising the technology, Leiomyosarcoma collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Leiomyosarcoma Pipeline Report
To explore more information on the latest breakthroughs in the Leiomyosarcoma Pipeline treatment landscape of the report, click here @ Leiomyosarcoma Pipeline Outlook
Leiomyosarcoma Overview
Leiomyosarcoma, or LMS, is a type of rare cancer that grows in the smooth muscles. The smooth muscles are in the hollow organs of the body, including the intestines, stomach, bladder, and blood vessels. In females, there is also smooth muscle in the uterus. These smooth muscle tissues help move blood, food, and other material through the body and work without you being aware. LMS is an aggressive cancer, which means it can grow quickly. LMS is found most often in the abdomen or in the uterus. LMS is a type of soft tissue sarcoma and makes up between 10% to 20% of soft tissue sarcoma cases. LMS is more common in adults than children. It is estimated that only about 20 to 30 children are diagnosed with LMS in the United States per year. LMS of the uterus affects about 6 per 1 million people per year in the United States.
Recent Developmental Activities in the Leiomyosarcoma Treatment Landscape
For further information, refer to the detailed Leiomyosarcoma Unmet Needs, Leiomyosarcoma Market Drivers, and Leiomyosarcoma Market Barriers, click here for Leiomyosarcoma Ongoing Clinical Trial Analysis
Leiomyosarcoma Emerging Drugs Profile
BAVENCIO is a human anti-programmed death ligand-1 (PD-L1) antibody. BAVENCIO has been shown in preclinical models to engage both the adaptive and innate immune functions. By blocking the interaction of PD-L1 with PD-1 receptors, BAVENCIO has been shown to release the suppression of the T cell-mediated antitumor immune response in preclinical models.10-12 In November 2014, Merck and Pfizer announced a strategic alliance to co-develop and co-commercialize BAVENCIO. Currently, it is in Phase II stage of clinical trial evaluation to treat Leiomyosarcoma.
AL3818 is a novel small molecule PTK inhibitor being developed by Advenchen Laboratories. Advenchen Laboratories is conducting a Phase III study to evaluate the safety and efficacy of AL3818 (anlotinib) hydrochloride in the treatment of metastatic or advanced alveolar soft part sarcoma (ASPS), leiomyosarcoma (LMS), and synovial sarcoma (SS).
Leiomyosarcoma Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Leiomyosarcoma. The companies which have their Leiomyosarcoma drug candidates in the most advanced stage, i.e. phase III include, Advenchen Laboratories.
Request a sample and discover the recent advances in Leiomyosarcoma Ongoing Clinical Trial Analysis and Medications, click here @ Leiomyosarcoma Treatment Landscape
Scope of the Leiomyosarcoma Pipeline Report
Dive deep into rich insights for drugs for Leiomyosarcoma Market Drivers and Leiomyosarcoma Market Barriers, click here @ Leiomyosarcoma Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Leiomyosarcoma Mergers and acquisitions, Leiomyosarcoma Licensing Activities @ Leiomyosarcoma Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/consulting/due-diligence-services